Theravance Biopharma (TBPH) Net Margin (2013 - 2026)
Theravance Biopharma's (TBPH) quarterly Net Margin came in at 28.08% in Q1 2026, up 6016.0% year-on-year from 0.46% in Q1 2025, and down 144.98% on a QoQ basis from 62.43% in Q4 2025.
Theravance Biopharma (TBPH) Net Margin (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Net Margin data on file, last reported at 28.08% in Q1 2026.
- On a quarterly basis, Net Margin rose 6016.0% year-over-year to 28.08% in Q1 2026; TTM through Mar 2026 was 74.81%, a 16419.0% increase from a year earlier, with the FY2025 full-year figure at 934.52%, up 102215.0% from the prior year.
- Net Margin for Q1 2026 stood at 28.08%, down from 62.43% in the prior quarter.
- Over the last five years, Net Margin for TBPH reached as high as 7445.92% in Q3 2022 and fell as low as 208.2% in Q1 2023.
- Historically, Net Margin has averaged 421.58% across 5 years, with a median of 30.19% in 2023.
- Across the five-year window, Net Margin surged 728977 bps in 2022 and slumped 750295 bps in 2023, its largest moves.
- Year by year, Net Margin stood at 26.58% in 2022, then tumbled by 214 bps to 30.19% in 2023, then sank by 174 bps to 82.79% in 2024, then jumped by 175 bps to 62.43% in 2025, then sank by 145 bps to 28.08% in 2026.
- Per Business Quant data, the three most recent Net Margin figures were 28.08% in Q1 2026, 62.43% in Q4 2025, and 18.08% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - | -28.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.08% |
| Dec 31, 2025 | 62.43% |
| Sep 30, 2025 | 18.08% |
| Jun 30, 2025 | 209.33% |
| Mar 31, 2025 | -88.24% |
| Dec 31, 2024 | -82.79% |
| Sep 30, 2024 | -75.28% |
| Jun 30, 2024 | -115.94% |
| Mar 31, 2024 | -80.42% |
| Dec 31, 2023 | -30.19% |
| Sep 30, 2023 | -57.03% |
| Jun 30, 2023 | -113.79% |
| Mar 31, 2023 | -208.20% |
| Dec 31, 2022 | 26.58% |
| Sep 30, 2022 | 7,445.92% |
| Jun 30, 2022 | 166.33% |
| Mar 31, 2022 | 118.16% |
| Dec 31, 2021 | 172.49% |
| Sep 30, 2021 | 156.15% |
| Jun 30, 2021 | 96.41% |